Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 septiembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Elimination of Transcoarctation Pressure Gradients Has No Impact on Left Ventricular Function or Aortic Shear Stress After Intervention in Patients With Mild Coarctation

Zahra Keshavarz-Motamed, Farhad Rikhtegar Nezami, Ramon A. Partida, Kenta Nakamura, Pedro Vinícius Staziaki, Eyal Ben-Assa, Brian Ghoshhajra, Ami B. Bhatt and Elazer R. Edelman

Objectives: This study sought to investigate the impact of transcatheter intervention on left ventricular function and aortic hemodynamics in patients with mild coarctation of the aorta (COA).

01 septiembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Acotec Drug-Coated Balloon Catheter

Xin Jia, Jiwei Zhang, Baixi Zhuang, Weiguo Fu, Danming Wu, Feng Wang, Yu Zhao, Pingfan Guo, Wei Bi, Shenming Wang and Wei Guo

Objectives: The aim of this study was to investigate the efficacy and safety of a new paclitaxel-coated balloon catheter in the treatment of stenotic or occluded femoropopliteal arteries.

01 agosto 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease

Daniele Giacoppo, Salvatore Cassese, Yukinori Harada, Roisin Colleran, Jonathan Michel, Massimiliano Fusaro, Adnan Kastrati and Robert A. Byrne

Objectives: This study sought to assess the risk of target lesion revascularization (TLR) and all-cause death at 12 months and at the maximum available follow-up. Secondary objectives included the identification of factors which could have influenced general findings.

01 agosto 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes

Ramon L. Varcoe, Olaf Schouten, Shannon D. Thomas and Andrew F. Lennox

Objectives: The aim of this study was to investigate the midterm performance of an everolimus-eluting, bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, California) for the treatment of focal tibial and distal popliteal lesions.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Sequential Proximal Optimizing Technique in Provisional Bifurcation Stenting With Everolimus-Eluting Bioresorbable Vascular Scaffold

François Derimay, Géraud Souteyrand, Pascal Motreff, Patrice Guerin, Paul Pilet, Jacques Ohayon, Olivier Darremont, Gilles Rioufol and Gérard Finet

Objectives: The aim of this fractal bifurcation bench study was to compare provisional bifurcation stenting with a “re-POT” sequence, comprising a proximal optimizing technique (POT), side branch inflation, and final POT, between a bioresorbable vascular scaffold (BVS) and a metallic stent.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery

Christian M. Kinstner, Johannes Lammer, Andrea Willfort-Ehringer, Wolfgang Matzek, Michael Gschwandtner, Domagoj Javor, Martin Funovics, Maria Schoder, Renate Koppensteiner, Christian Loewe, Robin Ristl and Florian Wolf

Objectives: The hypothesis that paclitaxel-eluting balloon angioplasty provides higher 1-year patency rates in femoropopliteal artery in-stent restenosis compared with standard percutaneous transluminal angioplasty (PTA) was tested.

01 junio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results

Johannes Lammer, Marc Bosiers, Koen Deloose, Andrej Schmidt, Thomas Zeller, Florian Wolf, Wouter Lansink, Antoine Sauguet, Frank Vermassen, Geert Lauwers, Dierk Scheinert, Jeffrey J. Popma, Robert McGreevy, Richard Rapoza, Lewis B. Schwartz and Michael R. Jaff

Objectives: This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold (BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) and superficial femoral artery (SFA).

01 enero 2018

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Sex-Based Assessment of Patient Presentation, Lesion Characteristics, and Treatment Modalities in Patients Undergoing Peripheral Vascular Intervention

Niveditta Ramkumar, Bjoern D. Suckow, Jeremiah R. Brown, Art Sedrakyan, Jack L. Cronenwett and Philip P. Goodney

Background: Limited evidence suggests that women and men might be treated differently for peripheral arterial disease. This analysis evaluated sex-based differences in disease presentation and its effect on treatment modality among patients who underwent endovascular treatment for peripheral arterial disease.

01 enero 2018

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. LumenRECON Guidewire: Pilot Study of a Novel, Nonimaging Technology for Accurate Vessel Sizing and Delivery of Therapy in Femoropopliteal Disease

Pradeep K. Nair, Jeffrey G. Carr, Brian Bigelow, Deepak L. Bhatt, Zachary C. Berwick and George Adams

Background: Proper vessel sizing during endovascular interventions is crucial to avoid adverse procedural and clinical outcomes. LumenRECON (LR) is a novel, nonimaging, 0.035-inch wire-based technology that uses the physics-based principle of Ohm’s law to provide a simple, real-time luminal size while also providing a platform for therapy delivery. This study evaluated the accuracy, reliability, and safety of the LR system in patients presenting for a femoropopliteal artery intervention.

01 septiembre 2017

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

Ahmed Saad, Sandra M.S. Herrmann, Alfonso Eirin, Christopher M. Ferguson, James F. Glockner, Haraldur Bjarnason, Michael A. McKusick, Sanjay Misra, Lilach O. Lerman and Stephen C. Textor

Background: Atherosclerotic renal artery stenosis reduces renal blood flow (RBF) and amplifies stenotic kidney hypoxia. Revascularization with percutaneous transluminal renal angioplasty (PTRA) and stenting often fails to recover renal function, possibly because of ischemia/reperfusion injury developing after PTRA. Elamipretide is a mitochondrial-targeted peptide that binds to cardiolipin and stabilizes mitochondrial function. We tested the hypothesis that elamipretide plus PTRA would improve renal function, oxygenation, and RBF in patients with atherosclerotic renal artery stenosis undergoing PTRA.

01 enero 2018

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries

Peter A. Schneider, John R. Laird, Gunnar Tepe, Marianne Brodmann, Thomas Zeller, Dierk Scheinert, Christopher Metzger, Antonio Micari, Ravish Sachar, Michael R. Jaff, Hong Wang, Melissa S. Hasenbank and Prakash Krishnan

Background: Randomized controlled trials have reported favorable 1-year outcomes with drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease when compared with standard percutaneous transluminal angioplasty (PTA). Evidence remains limited on the durability of the treatment effect with DCBs in the longer term.

01 octubre 2017

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry

Alexander C. Fanaroff, Pratik Manandhar, David R. Holmes, David J. Cohen, J. Kevin Harrison, G. Chad Hughes, Vinod H. Thourani, Michael J. Mack, Matthew W. Sherwood, W. Schuyler Jones and Sreekanth Vemulapalli

Background: Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknown.

01 septiembre 2017

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study

Thomas Zeller, Ralf Langhoff, Krishna J. Rocha-Singh, Michael R. Jaff, Erwin Blessing, Beatrice Amann-Vesti, Marek Krzanowski, Patrick Peeters, Dierk Scheinert, Giovanni Torsello, Sebastian Sixt and Gunnar Tepe

Background: Studies assessing drug-coated balloons (DCB) for the treatment of femoropopliteal artery disease are encouraging. However, challenging lesions, such as severely calcified, remain difficult to treat with DCB alone. Vessel preparation with directional atherectomy (DA) potentially improves outcomes of DCB.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.